ALGN vs EW vs SOLV Stock Comparison

Align Technology, Edwards Lifesciences and Solventum Prices as of Nov 13, 2026 Peers: Industry group
ALGN Align Technology Inc
$168.32 +16.5% 1M +20.7% 1Y
Market cap
$11.89B
P/E
24.2x
Revenue (TTM)
$4.16B
Div. yield
–
Dental Healthcare
1 win
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.83B
P/E
60.9x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
9 wins
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.27B
P/E
97.9x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
1 win

Head to Head

11 decided of 12

Edwards Lifesciences leads on 9 of the 12 questions below (Edwards Lifesciences 9, Align Technology 1, Solventum 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALGNEWSOLVLeader
Larger companyMarket capitalisation $11.89B $61.83B $15.27B EW
Cheaper on earningsLower P/E, profitable companies only 24.2x 60.9x 97.9x ALGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 15.5x 37.6x 12.8x SOLV
Faster revenue growthRevenue growth, trailing twelve months +4.4% +13.4% -2.8% EW
More profitableNet margin, trailing twelve months 11.8% 15.2% 1.9% EW
Better return on capitalReturn on invested capital — 8.7% 4.2% EW
Less leveragedLower net debt / EBITDA — -2.5x 4.7x EW
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +20.7% +24.5% +18.4% EW
Better 5-year returnAnnualised price return, 5 years -24.6%/yr -1.6%/yr — EW
Less volatileAnnualised volatility, 1 year 40.3% 25.5% 30.1% EW
Higher overall scoreMean of the five percentile scores vs peers 70/100 77/100 51/100 EW

Percentile Scorecard

ALGNEWSOLV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALGNEWSOLV
Valuation 85 #37 of 243 61 #96 of 243 70 #74 of 243
Growth 38 #142 of 228 57 #99 of 228 3 #221 of 228
Profitability 87 #29 of 222 96 #10 of 222 71 #66 of 222
Financial Health 48 #130 of 248 87 #34 of 248 15 #210 of 248
Shareholder Returns 92 #13 of 158 84 #26 of 158 94 #10 of 158
Overall 70 77 51
  • ALGN ranked among 252 companies in Medical Devices and Diagnostics
  • EW ranked among 252 companies in Medical Devices and Diagnostics
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALGNEWSOLVSPY
1 month +16.5%+24.0%+2.0% -2.0%
3 months -7.2%+17.0%+0.5% -2.8%
6 months +7.0%+31.7%+19.9% +2.0%
Year to date +7.8%+25.7%+12.4% +10.6%
1 year +20.7%+24.5%+18.4% +12.2%
3 years -17.0%+62.9%— +68.1%
3 years, per year -6.0%+17.7%— +18.9%
5 years -75.5%-7.6%— +61.4%
5 years, per year -24.6%-1.6%— +10.1%
10 years +83.9%+253.3%— +248.5%
10 years, per year +6.3%+13.5%— +13.3%

Risk

MeasureALGNEWSOLVSPY
Volatility, 1Y 40.3%25.5%30.1% 13.6%
Downside volatility, 1Y 37.6%24.7%29.3% 13.9%
Beta vs S&P 500, 1Y 1.330.580.61 1.00
Return / volatility, 1Y 0.510.960.61 0.90
Max drawdown, 5Y -82.0%-54.3%-40.0% -25.4%
From 52-week high -14.8%0.0%-3.7% -3.2%
52-week high $197.51$107.18$92.45 $779.14
52-week low $132.28$75.87$62.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALGNEWSOLV
P/E now vs peer median 24.3xmedian 26.5x 60.9xmedian 26.5x 97.5xmedian 26.5x
P/S now vs peer median 2.9xmedian 2.7x 9.2xmedian 2.7x 1.9xmedian 2.7x
EV/EBITDA now vs peer median 12.5xmedian 18.4x 35.8xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 19.7xmedian 25.4x 43.3xmedian 25.4x 156.0xmedian 25.4x
P/B now vs peer median 2.8xmedian 2.5x 5.6xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median 1.78median 0.98 -6.65median 0.98 —median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALGNEWSOLV
Revenue $4.16B $6.67B $8.16B
Gross profit $2.88B $5.21B $4.47B
Operating income $620.46M $1.44B $454.00M
Net income $491.87M $1.02B $156.00M
Free cash flow $602.50M $1.42B –
R&D $377.60M $1.09B $723.00M
EPS (diluted) $6.93 $1.76 $0.91
Cash & equivalents $1.14B $3.11B $451.00M
Total debt – $598.80M $5.07B
Shares (diluted) 71.02M 577.60M 170.80M
Enterprise value $7.49B $45.04B $12.98B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALGNEWSOLV
P/E 24.3x 60.9x 97.5x
P/FCF 19.7x 43.3x 156.0x
P/Operating cash flow 15.9x 35.9x 48.8x
P/S 2.9x 9.2x 1.9x
P/B 2.8x 5.6x 3.1x
P/Tangible book 2.8x 6.3x 6.1x
EV/EBITDA 12.5x 35.8x 20.3x
EV/EBIT 17.3x 40.0x 43.5x
EV/Revenue 2.6x 8.6x 2.4x
EV/FCF 17.8x 40.5x –
EV/Operating cash flow 14.3x 33.6x 63.7x
PEG (3Y EPS CAGR) 1.78 -6.65 –

Growth

14 metrics
MetricALGNEWSOLV
Revenue growth (1Y) 4.4% 13.4% -2.8%
Revenue CAGR (3Y) 3.0% 16.9% –
Gross profit growth (1Y) 5.5% 13.2% -1.6%
Gross profit CAGR (3Y) 2.7% 13.7% –
Operating income growth (1Y) 16.1% 1.1% -79.3%
Operating income CAGR (3Y) 2.0% 5.8% –
Net income growth (1Y) 30.0% -25.2% -89.8%
Net income CAGR (3Y) 10.7% -10.6% –
EPS growth (1Y) 32.6% -24.5% -89.5%
EPS CAGR (3Y) 13.6% -9.2% –
Operating cash flow growth (1Y) 14.3% 68.9% -37.1%
Operating cash flow CAGR (3Y) -5.3% 18.1% –
Free cash flow growth (1Y) 6.3% 77.1% –
Free cash flow CAGR (3Y) -4.2% 20.8% –

Profitability

14 metrics
MetricALGNEWSOLV
Gross margin 69.1% 78.0% 54.8%
EBITDA margin 20.6% 24.2% 11.9%
Operating margin 14.9% 21.6% 5.6%
Pretax margin 15.5% 21.5% 2.1%
Net margin 11.8% 15.2% 1.9%
FCF margin 14.5% 21.3% –
Operating cash flow margin 18.0% 25.7% 3.8%
Return on equity 11.5% 9.4% 3.3%
Return on assets 7.6% 7.2% 1.1%
Return on invested capital – 8.7% 4.2%
Return on capital employed 13.6% 11.6% 4.3%
Asset turnover 0.6x 0.5x 0.6x
Cash conversion (OCF / net income) 1.5x 1.7x 2.0x
Stock comp / revenue 4.1% 2.6% 2.1%

Financial Health

11 metrics
MetricALGNEWSOLV
Debt / assets – 4.2% 35.8%
Debt / equity – 0.1x 1.1x
Net debt / EBITDA – -2.5x 4.7x
Debt / FCF – 0.4x –
Liabilities / assets 34.0% 22.5% 66.1%
Equity / assets 66.0% 77.5% 33.9%
Interest coverage – – –
Current ratio 1.4x 4.6x 1.0x
Quick ratio 1.2x 3.5x 0.5x
Cash ratio 0.6x 2.9x 0.1x
Altman Z-score 4.89 14.42 1.85

Shareholder Returns

7 metrics
MetricALGNEWSOLV
Dividend yield – – –
Net buyback yield 2.3% 0.9% 2.7%
Shareholder yield 2.3% 0.9% 2.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALGNEWSOLV
Forward P/E 15.5xFY2026 37.6xFY2026 12.8xFY2026
EPS, next fiscal year $10.86FY2026 $2.85FY2026 $6.93FY2026
EPS growth, next FY +3.3%FY2026 +11.3%FY2026 +13.4%FY2026
EPS growth, the year after +16.6% +12.6% +15.3%
Revenue, next fiscal year $3.84BFY2026 $7.28BFY2026 $7.71BFY2026
Revenue growth, next FY -4.7%FY2026 +19.9%FY2026 -7.3%FY2026
Revenue growth, the year after +3.1% -2.2% +5.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALGNEWSOLV
Held by institutions 100.0% 90.6% 73.9%
Institutions holding 678 1,326 882
Change in shares held, QoQ +4.2% +20.4% -0.9%
Institutions buying 293 641 370
Institutions selling 268 456 286
Buyers to sellers 1.09 1.41 1.29

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALGNEWSOLV
ALGN 1.00 0.30 0.53
EW 0.30 1.00 0.27
SOLV 0.53 0.27 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALGN, EW and SOLV?

Edwards Lifesciences (EW) is the largest by market capitalisation: Align Technology (ALGN) $11.89B, Edwards Lifesciences (EW) $61.83B, Solventum (SOLV) $15.27B.

Which stock is cheaper, ALGN, EW and SOLV?

Align Technology (ALGN) trades on the lowest price-to-earnings ratio (Align Technology (ALGN) 24.2x, Edwards Lifesciences (EW) 60.9x, Solventum (SOLV) 97.9x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Align Technology (ALGN) 15.5x, Edwards Lifesciences (EW) 37.6x, Solventum (SOLV) 12.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Align Technology (ALGN) +4.4%, Edwards Lifesciences (EW) +13.4%, Solventum (SOLV) -2.8%.

Which company is more profitable?

Edwards Lifesciences (EW) has the highest net margin (Align Technology (ALGN) 11.8%, Edwards Lifesciences (EW) 15.2%, Solventum (SOLV) 1.9%). On return on invested capital, Edwards Lifesciences (EW) leads (Edwards Lifesciences (EW) 8.7%, Solventum (SOLV) 4.2%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Align Technology (ALGN) +20.7%, Edwards Lifesciences (EW) +24.5%, Solventum (SOLV) +18.4%. Over five years, Edwards Lifesciences (EW) compounded fastest (Align Technology (ALGN) -24.6%/yr, Edwards Lifesciences (EW) -1.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Align Technology (ALGN) 40.3%, Edwards Lifesciences (EW) 25.5%, Solventum (SOLV) 30.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALGN, EW and SOLV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Edwards Lifesciences (EW) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.